On January 10, 2025, bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced an amendment to the employment agreement of its Chief Executive Officer, Maria Zannes. The company’s Compensation Committee approved the amendment, which includes an increase in Zannes’ annual base salary to $300,000. This adjustment is retroactive to November 1, 2024.
The specifics of the amendment were outlined in an 8-K filing with the Securities and Exchange Commission. A copy of the full text of the Amendment, marked as Exhibit 10.1, was included in the filing for reference.
For further details regarding this update and the corresponding employment agreement, interested parties can refer to the official filing on the SEC’s website.
In other related news, bioAffinity Technologies, Inc. is listed on the Nasdaq Stock Market as BIAF for its Common Stock and BIAFW for its Tradeable Warrants to purchase Common Stock.
This news follows the company’s continued efforts to strengthen its management team and position itself for future growth and success in the market.
END.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read bioAffinity Technologies’s 8K filing here.
About bioAffinity Technologies
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Featured Articles
- Five stocks we like better than bioAffinity Technologies
- Health Care Stocks Explained: Why You Might Want to Invest
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is MarketRank™? How to Use it
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- ETF Screener: Uses and Step-by-Step Guide
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
